When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Howard (Jack) West, MD, Medical Director, Thoracic Oncology Program Swedish Cancer Institute, President & CEO, Global Resource for Advancing Cancer Education (GRACE), Seattle, WA, discusses lung cancer in…
A study presented at the American Association for Cancer Research meeting showed progression of androgen-independent prostate cancer was significantly inhibited in mice by a combination of atorvastatin (Lipitor)…
Howard (Jack) West, MD, Medical Director, Thoracic Oncology Program Swedish Cancer Institute, President & CEO, Global Resource for Advancing Cancer Education (GRACE), Seattle, WA, discusses treatment therapies and…
Howard (Jack) West, MD, Medical Director, Thoracic Oncology Program Swedish Cancer Institute, President & CEO, Global Resource for Advancing Cancer Education (GRACE), Seattle, WA, discusses his website OncTalk,…
When a child is diagnosed with cancer, everyone in the family needs healing… including the siblings! SuperSibs! is a national not-for-profit whose mission is to ensure that the…
A new analysis of data from a multicenter clinical trial suggests that chemotherapy-induced anemia significantly increases the risk of local relapse in premenopausal early-stage breast cancer. References and…
A new study shows that the aromatase inhibitor letrozole can prevent late recurrence of breast cancer. References and Resources Goss P, et al. Late extended adjuvant treatment with…
Statin use at the time of ovarian cancer surgery was associated with a 50% increase in the duration of progression-free survival and with more than a year of…
The Oncologic Drug Advisory Committee said the FDA should mandate a restricted distribution system for cancer patients given erythropoiesis-stimulating agents. References and Resources FDA.gov Sponsored by The Doctor’s…
Results of a Gynecologic Oncology Group study suggest that for patients with recurrent cervical cancer, bevacizumab has demonstrated activity and promise as an option for second or third…
